Table 1.
PJP cases: underlying and predisposing conditions
| Patient | Age/sex | Diagnosis (disease status) | Comorbidities | Pre‐FCR treatment | Completed FCR cycles | Corticosteroid within 1 month of PJP diagnosis | PJP prophylaxis during and post‐FCR |
|---|---|---|---|---|---|---|---|
| 1 | 58/M |
CLL (remission) |
Nil | Chlorambucil | 6/6 | No |
During: Yes Post: No |
| 2 | 71/M |
Mantle cell lymphoma (remission) |
Myelodysplasia | Hyper‐CVAD | 3/4 | No |
During: No Post: No |
| 3 | 64/M |
Follicular lymphoma (remission) |
Mild pulmonary fibrosis Lung cancer RUL lobectomy |
Chlorambucil, Autologous SCT | 6/6 |
Prednisolone 25 mg/d (3 wk) |
During: Yes Post: No |
| 4 | 80/M |
Mantle cell lymphoma (active) |
Prostate cancer Hypothyroidism |
R‐CHOP, R‐CEOP | 6/6 | No |
During: No Post: No |
| 5 | 66/F |
CLL (remission) |
Nil | No | 6/6 | No |
During: Yes Post: No |
| 6 | 62/F |
CLL (active) |
Hypogammaglobulinaemia | FCR | 3/3 | No |
During: Yes Post: No |
| 7 | 70/F |
Mantle cell lymphoma (remission) |
Ovarian cancer Splenectomy |
No | 5/5 | No |
During: Yes Post: No |
| 8 | 66/M |
Follicular lymphoma (remission) |
COPD | R‐CHOP | 4/4 | No |
During: Yes Post: No |
M indicates male; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; RUL, right upper lobe; SCT, stem cell transplant; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R‐CEOP, rituximab, cyclophosphamide, doxorubicin, etoposide, prednisolone; d, day; w, weeks; F, female; COPD, chronic obstructive pulmonary disease.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.